Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring

Alroughani, Raed A ; Aref, Hany ; Bohlega, Saeed A ; Dahdaleh, Maurice P ; Feki, Imed ; Al Jumah, Mohammed A ; Al-Kawi, Muhammad Z ; Koussa, Salam F ; Sahraian, Mohamad A ; Alsharoqi, Isa A ; Yamout, Bassem I 


Abstract


Natalizumab, a highly specific α4-integrin antagonist, , has recently been registered across the Middle East and North Africa region. It improves clinical and magnetic resonance imaging (MRI) outcomes and reduces the rate of relapse and disability progression in relapsing-remitting multiple sclerosis (MS). Natalizumab is recommended for patients who fail first-line disease-modifying therapy or who have very active disease. Progressive multifocal leukoencephalopathy is a rare, serious adverse event associated with natalizumab. We aim to develop regional recommendations for the selection and monitoring of MS patients to be treated with natalizumab in order to guide local neurological societies.


Other data

Issue Date 12-Feb-2014
Journal BMC neurology 
URI http://research.asu.edu.eg/handle/123456789/1852
DOI 27
14
1471-2377
10.1186/1471-2377-14-27


Recommend this item

CORE Recommender
4
Citations

3
Views


Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.